CD28 Superagonists: What Makes the Difference in Humans?
Open Access
- 1 May 2008
- journal article
- editorial
- Published by Elsevier BV in Immunity
- Vol. 28 (5), 591-595
- https://doi.org/10.1016/j.immuni.2008.04.003
Abstract
No abstract availableKeywords
Funding Information
- Bundesministerium für Bildung und Forschung
This publication has 19 references indexed in Scilit:
- Siglecs and their roles in the immune systemNature Reviews Immunology, 2007
- Mitogenic CD28 Signals Require the Exchange Factor Vav1 to Enhance TCR Signaling at the SLP-76-Vav-Itk SignalosomePublished by The American Association of Immunologists ,2007
- Manipulation of Regulatory T‐Cell Number and Function with CD28‐Specific Monoclonal AntibodiesAdvances in Immunology, 2007
- Lessons from TGN1412The Lancet, 2006
- Transient accumulation of human mature thymocytes and regulatory T cells with CD28 superagonist in “human immune system” Rag2-/-γc-/- miceBlood, 2006
- CD28-mediated co-stimulation: a quantitative support for TCR signallingNature Reviews Immunology, 2003
- Mitogenic signals through CD28 activate the protein kinase Ctheta-NF-kappaB pathway in primary peripheral T cellsInternational Immunology, 2003
- Topological Requirements and Signaling Properties of T Cell–activating, Anti-CD28 Antibody SuperagonistsThe Journal of Experimental Medicine, 2003
- Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonistEuropean Journal of Immunology, 2003
- Autonomous induction of proliferation, JNK and NF-κB activation in primary resting T cells by mobilized CD28European Journal of Immunology, 2000